Drug guidance
Romosozumab and teriparatide for treating osteoporosis
Condition
Musculoskeletal
4 June 2025
Published on 01 Jun 2023
Last Updated on 04 Jun 2025
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has not recommended:
Romosozumab or teriparatide reference biologic (Forteo) for inclusion on the MOH List of Subsidised Drugs for treating postmenopausal women with osteoporosis who are at high risk for fracture; and
Teriparatide reference biologic (Forteo) for inclusion on the MOH List of Subsidised Drugs for treating men with primary or hypogonadal osteoporosis who are at high risk for fracture, or patients with glucocorticoid-induced osteoporosis who are at high risk for fracture
due to uncertain extent of clinical benefit and unfavourable cost-effectiveness compared with subsidised alternatives.
Romosozumab and teriparatide for treating osteoporosis (Updated 4 Jun 2025) [PDF, 152 KB]
PES Anabolic drugs for treating osteoporosis (Updated 4 Jun 2025) [PDF, 117 KB]